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Introduction
The role of sphingolipid compounds is increasingly recognized in cancer. The metabolites ceramide, sphingosine and sphingosine 1-phosphate (S1P) have crucial roles in intracellular and extracellular signaling.(1) Sphingosine kinase 1 (SphK) catalyzes the phosphorylation of sphingosine to form sphingosine 1-phosphate (S1P).(2) S1P acts downstream as a second messenger and via G protein-coupled receptors regulates multiple cellular processes including apoptosis inhibition, cell proliferation and angiogenesis.(2) SphK therefore regulates a rheostat, balancing the effects of pro-apoptotic ceramide and pro-proliferative S1P. Inhibiting SphK and downregulating S1P is thus a rational therapeutic target in cancer. The exact mechanism of its action is, however, uncertain. Safingol has previously been studied extensively as an inhibitor of Protein Kinase C, although the K i is somewhat higher at 33 µM for PKC than for SphK. (8) Inhibition of SphK is a plausible mechanism of action based on safingol's ability to increase ceramide levels, alter the S1P/ceramide rheostat, and decrease tumor cell survival. (9) We have previously reported a phase I study of safingol in combination with doxorubicin. (10) Doses of safingol up to 120 mg/m 2 were administered every three weeks with no dose-limiting toxicity observed. However, the clinical trial was terminated before the maximum tolerated dose
Research. The primary objective of this trial was to determine the maximum tolerated dose (MTD) of safingol when administered in combination with cisplatin in patients with advanced solid tumors.
Safingol was administered over 60 to 120 minutes, prior to cisplatin dosing. Secondary objectives were to investigate the clinical pharmacokinetics of safingol and cisplatin, to study the pharmacodynamics of SphK inhibition, and to obtain preliminary data on the therapeutic activity of this regimen.
Patients and Methods
Eligibility. Eligible patients were ≥ 18 years of age with a diagnosis of pathologically confirmed measurable or evaluable advanced solid tumor, with disease that was refractory to standard therapy or for which there was no standard therapy. Eligible patients had Karnofsky performance status of ≥ 70%, total white blood cell count ≥ 3,500/mm The protocol was approved by the Institutional Review Board of MSKCC and all patients provided written informed consent.
Treatment plan.
This was an open-label, non-randomized, dose escalation study to determine the maximum tolerated dose (MTD) of intravenous safingol when administered 1 hour prior to a standard dose of cisplatin, once every 21 days.
Groups of three to six patients were treated sequentially according to the dose escalation in Table 1 . Safingol was administered as a 60-to 120-minute IV infusion, depending on the volume of the dose. 60 minutes after the completion of the safingol infusion, cisplatin was given as a 60-minute infusion. Each treatment cycle lasted 3 weeks, except for Cycle 1, which lasted 4 weeks. In Cycle 1, in order to assess safety and pharmacokinetics, safingol was given alone on Day 1. Following this, on Day 8 of Cycle 1, both safingol and cisplatin were administered.
Because of concerns for hemolysis, urinalysis, haptoglobin, RBC morphology and CBC were assessed before and after the first infusion of safingol.
All treatments were administered in the outpatient setting and, once assigned to a dose level, intra-patient dose escalation was not permitted. (14) and sphingolipid profile (15) was measured by high-performance liquid chromatography (HPLC) with mass spectroscopy (HPLS/MS) for quantitation. Pharmacokinetic parameters were estimated using a noncompartmental model.
Results

Patient characteristics. From April 2004 to October 2008, 43 patients with advanced solid
tumors were registered and treated. Two of these were not evaluable for determining DLT because they did not complete one cycle (4 weeks) of treatment. The reasons were clinical deterioration (1 patient) and adverse effects of cisplatin (1 patient). A further four patients were not evaluable for response because they did not continue treatment until the first restaging scan. The reasons were withdrawal of consent due to adverse events (3 patients) and clinical deterioration (1 patient). In total, 41 patients were evaluable for toxicity and 37 for response.
The median age was 54 years (range, 33-82 years) and the median Karnofsky performance status was 80% (range, 70-100%). There were 17 men and 26 women. The cancers treated and patient numbers were colorectal (11), adrenal cortical (7), sarcoma (6), pancreas (4), melanoma (3), hepatocellular (3), gastric (3), and others (6). 26 patients (60%) had received prior chemotherapy. 6 patients (14%) had received prior cisplatin. Table 3 , one DLT occurred (grade 3 AST/ALT) among six patients. Thus, the MTD had been reached. The DLT rate for the MTD cohort was 17% (1/6). This was considered acceptable using pre-specified guidelines since the upper limit of the 95% posterior interval was 40%. (16) Pharmacokinetics. Blood samples for pharmacokinetic analyses were obtained for 39 patients. Table 4 no statistically significant change in PK parameters from day 1 to day 8 and thus no evidence for any significant drug-drug interaction with cisplatin.
Cycle 1 toxicities.
Pharmacodynamics. Blood samples were also assayed for levels of sphingosine-1-phophate (S1P). As an inhibitor of SphK, safingol would be expected to decrease S1P levels, which thus serve as a pharmacodynamic readout. The results are shown in figure 2A . The average S1P levels 1 hour and 4 hours after safingol treatment are shown, with patients grouped by safingol dose cohort. S1P levels are normalized to the pre-treatment levels for each patient cohort and standard error bars are shown. The results show a dose-dependent decrease in S1P levels. Antitumor activity. 37 patients were evaluable for response assessment. The best response was stable disease in 6 patients for on average 3.3 m (range 1.8 -7.2 m). One patient with adrenal cortical cancer had significant regression of liver and lung metastases (Figure 3 ). This patient, treated in cohort 3, developed grade 3 fatigue and hyponatremia. This was considered related to the cisplatin treatment, not to the safingol, and led to the modification of the cisplatin dose for subsequent cohorts. Because of these side effects, the patient withdrew consent and did not receive a second cycle of therapy. She was therefore not evaluable for the response endpoint as defined in the protocol. Nonetheless, her follow-up CT scans over several months with no further therapy demonstrated a major decrease in the size and number of metastases.
This would have qualified as a confirmed partial response by RECIST and the response lasted 5.8 months. We also note that the other patient with significant clinical benefit, a long period of stable disease (7.2 m), also had adrenal cortical cancer. The doses of safingol administered here were significantly higher than those in the other clinical trial of safingol with doxorubicin in which no hepatic toxicity was observed. In that study, safingol doses did not exceed 120 mg/m 2 due to drug supply constraints. Here we identify for the first time a true MTD associated with safingol treatment. In the previous study, one case of hemolysis was considered a possible toxicity of safingol. In the current study, despite careful monitoring, no hemolysis was observed in any patient.
Extensive pharmacokinetic sampling was performed. There was no significant interaction of safingol with cisplatin. For patients treated in cohorts 1-7, safingol C max and AUC were not significantly changed from Day 1, when safingol was administered alone, to Day 8, when safingol was administered with cisplatin (Table 4) . Based on this observation, pharmacokinetic sampling was therefore limited to only Day 1 for those patients treated in cohorts 8-10. Treatment with safingol and cisplatin was associated with significant decreases in plasma levels of S1P. One possible explanation is that safingol effectively inhibited SphK leading to decreased S1P levels. However, S1P biology is complex and other mechanisms must be considered. SphK, when activated, translocates to the cell membrane where its substrate, sphingosine, is located.(17) S1P is generated and transported extracellularly for autocrine and paracrine signaling and can also act intracellularly through histone deacetylases to regulate gene expression (18)(19) S1P levels are closely regulated with tissue S1P generally low, and plasma S1P generally high. (20, 21) The high levels of S1P normally measured in plasma are derived from multiple sources, including platelets, erythrocytes and the vascular endothelium. (22) (23) (24) (25) Thus, alternative mechanisms may explain the association between safingol administration and S1P levels. The observed changes in plasma S1P could be the result of decreased S1P production or decreased S1P release from either tumor or normal tissues such as hematopoietic or endothelial cells. An increase in S1P utilization or degradation by tumor or normal tissue could also explain the result. Our pharmacokinetic data only allow us to comment on plasma levels of S1P. Whether these reflect intra-tumoral levels of S1P is unknown. Other potential causes of S1P reduction include an effect of safingol on a target other than SphK, or even a nonspecific effect of the drug formulation.
Nevertheless, the results show that high plasma levels of safingol can be achieved and sustained for up to 4 hours after dosing. These levels are in the range predicted to effectively inhibit SphK. Sustained levels of safingol in plasma were associated with decreased S1P, consistent with the putative mechanism of action. Whether S1P suppression correlates with intracellular or intratumoral SphK activity is unknown and would require tumor biopsies to elucidate.
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